Bioblast Pharma announces sale of Trehalose development programs to Seelos Therapeutics
Bioblast Pharma announced the sale of its Trehalose clinical development programs to Seelos Therapeutics. Seelos will pay Bioblast $3.5 million in two instalments; $1.5 million payable upon closing of the sale and the other $2.0 million will be paid upon the first anniversary of the sale. February 19, 2019